The Innovation Plenary will discuss new HIV prevention modalities under study. Long acting injectables, a new modality for HIV Treatment and PrEP, is making its way into the box of tools to treat and prevent HIV infection. How can injectables be effective in our communities? Will injectables help to increase PrEP uptake among Black and Latino MSM? Yet a new delivery mechanism brings its own set of challenges. However, the question remains, “Are we ready to give injectable medicine a shot?
The MOSAICO VACCINE STUDY is the largest HIV study ever. Results from this study might be available in the next five years. How will testing of a vaccine intervention help to highlight the role that biomedical prevention tools such as PrEP, PEP, Treatment as Prevention (TasP), and U=U have in ending the epidemic? The second part of this plenary is designed to increase your understanding of HIV vaccines, and how they fit into the context of HIV prevention broadly. It will help us know about the current vaccine stories, how vaccines are developed, the making of a HIV vaccine and how might it work.